Essential thrombocythaemia: challenges and evidence-based management (Q36200476)

12 August 2017

1 reference

title

Essential thrombocythaemia: challenges and evidence-based management (English)

1 reference

12 August 2017

Claire N Harrison

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 July 2005

1 reference

British Journal of Haematology

12 August 2017

published in

1 reference

12 August 2017

volume

130

1 reference

12 August 2017

1 reference

12 August 2017

page(s)

153-165

1 reference

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

Modern management of myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

Clonal hemopoiesis and risk of thrombosis in young female patients with essential thrombocythemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

The Philadelphia translocation and pre-existing myeloproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

The role of hydroxyurea in sickle cell disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

Current trends in essential thrombocythaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

Interphase molecular cytogenetic screening for chromosomal abnormalities of prognostic significance in childhood acute lymphoblastic leukaemia: a UK Cancer Cytogenetics Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

Increased risk for vascular complications in PRV‐1 positive patients with essential thrombocythaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

Efficacy and safety of low-dose aspirin in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

No treatment for low-risk thrombocythaemia: results from a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

Long-term use of anagrelide in young patients with essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

The World Health Organization (WHO) classification of the myeloid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

Megakaryocyte c-Mpl expression in chronic myeloproliferative disorders and the myelodysplastic syndrome: immunoperoxidase staining patterns and clinical correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

Should a platelet limit of 600 x 109/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05543.X

10.1111/J.1365-2141.2005.05543.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference